At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Post-Mkt 04-15 19:11:24 EDT
3.88
-0.02
-0.51%
盘后3.88
+0.000.00%
16:05 EDT
| High4.01 | Low3.81 | Vol403.78K |
| Open3.89 | D1 Closing3.90 | Amplitude5.13% |
| Mkt Cap343.78M | Tradable Cap228.76M | Total Shares88.60M |
| T/O1.57M | T/O Rate0.68% | Tradable Shares58.96M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis
Reuters · 04-09
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis
THOMSON REUTERS · 04-09
Amylyx Pharmaceuticals Inc: Amylyx Expects Early Cohort Data From Lumina This Year
THOMSON REUTERS · 04-09
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
Business Wire · 04-09
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Mizuho
Dow Jones · 04-07
Mizuho Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Raises Price Target to $7 From $3
MT Newswires Live · 04-07
Amylyx Pharmaceuticals Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $7 From $3
THOMSON REUTERS · 04-07
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
Zacks · 03-07
Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03-05
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
TIPRANKS · 03-05
BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth
Reuters · 03-04
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03-04
BUZZ-Amylyx Pharmaceuticals falls on quarterly loss
Reuters · 03-04
Amylyx files $300M mixed securities shelf
TIPRANKS · 03-04
Amylyx Pharmaceuticals Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing
THOMSON REUTERS · 03-04
Amylyx Pharma Q4 EPS $(0.55) Misses $(0.52) Estimate
Benzinga · 03-04
BRIEF-Amylyx Pharmaceuticals Q4 EPS USD -0.55
Reuters · 03-04
Amylyx Pharmaceuticals Inc - Expected Cash Runway Through End of 2026
THOMSON REUTERS · 03-04
Amylyx Pharmaceuticals Q4 EPS USD -0.55
THOMSON REUTERS · 03-04
Press Release: Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Dow Jones · 03-04
Introduction
Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App